⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockUnited StatesNasdaqGS

GILD

Gilead Sciences, Inc.

Healthcare · Drug Manufacturers - General

145.65USD

-0.9900 (-0.68%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗
ProfileRatiosRevenue & EPS
Reading financial statements from SEC filings…
A first visit to a security takes a few seconds.
Fiscal Year End12/2025
Last Quarter End06/2026 Q2
Current/T12M(USD)
1)

Issue Data

Last PxUSD / 145.65
P/E—
Dvd Ind Yld2.2%
P/B15.27
P/S5.9
Curr EV/T12M EBITDA13.8
Mkt Cap (USD)180.6B
Curr EV (USD)201.9B
2)

Per Share Data

EPS T12M-2.67
DPS3.27
Bk Val Per Sh9.53
Rev/Sh24.50
Cash/Sh3.94
Curr Shares Out1,240.0M
FCF/Sh10.41
3)

Cash Flow Analysis

P/CF13.3
Curr P/FCF14.0
CF/NI-4.2
Dvd P/O-125.6%
Cash Gen/Cash Reqd2.9
Csh Dvd Cov3.3
CFO/Sales44.5%
Eff Interest Rate3.9%
4)

Growth Potential

Dil EPS 1Y Gr1684.2%
Cap 1Y Gr3.5%
BPS 1Y Gr17.4%
R&D To Sales30.0%
Retention Rate225.6%
Rev 1Y Gr2.4%
FCF 1Y Gr-8.2%
Assets 1Y Gr0.0%
5)

Profitability

EBITDA-2.1B
EBIT-2.5B
Operating Margin-8.2%
Pretax Margin-6.4%
Net Margin-10.6%
ROA-6.2%
ROE-20.6%
ROC—
Asset Turnover0.58
6)

Structure

Current Ratio1.27
Quick Ratio0.90
Debt/Assets53.2%
Debt/Com Eq221.9%
Net Debt/EBITDA-9.80
Tot Debt/Capital68.9%
Gross Margin79.6%
EBIT/Int Exp-2.5

Returns and turnover use the AVERAGE balance over the year, not the closing snapshot. Growth rates compare the two most recent fiscal years.